Search Follow us

Addex Therapeutics (ADXN)

Business description

Addex Therapeutics is a Swiss biotech company with a leading position in the identification of allosteric modulators with activity in CNS, inflammatory and metabolic disease. Its pipeline includes two Phase II compounds, with one partnered with J&J.

Dipraglurant data supports orphan disease focus

Update | Pharmaceutical & healthcare | 19/04/2013

Positive preclinical data for dipraglurant in dystonia supports progression into a Phase II study for rare dystonias in H113. Phase II results (Q413), if positive, could trigger a larger Phase IIb trial (2014). Addex continues to target a dipraglurant partnership for Parkinson’s disease (PD), which may be informed by upcoming Phase II results (Q213) for Novartis’s competing mGlu5 inhibitor (AFQ056). While Addex is currently financed to end-2013, potential deals and/or financings could extend the cash runway. A planned NASDAQ listing (timing tbc) in our view, could be a prelude to a financing.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.CHF32.9m
Last closeCHF2.140
High / Low (52 weeks)CHF2.5 / CHF1.8
Stock market listingSW
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(1.8)(4.9)(12.7)
Relative *(4.8)(8.9)(23.3)

* % Relative to local index